3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
7
Triple Negative Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Squamous Cell Carcinoma of Head and Neck
2
Osteosarcoma
2
Lung Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Pathologic Complete Response
1
Neutropenia
1
Neoplasms
1
NSCLC
1
Myelosuppression
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Advanced Squamous Non-Small-Cell Lung Cancer
1
Interventions
pembrolizumab
31
Gemcitabine
26
Nivolumab
20
atezolizumab
16
Cisplatin
15
avelumab
14
Carboplatin
12
Docetaxel
10
enfortumab vedotin
8
Magnetic Resonance Spectroscopy
8
durvalumab
7
Specimen Handling
7
Paclitaxel
7
Ipilimumab
6
toripalimab
5
pemigatinib
5
cabozantinib
5
vinflunine
4
sacituzumab govitecan
4
Taxes
4
Pemetrexed
4
tislelizumab
3
cabazitaxel
3
Standard of Care
3
Mitomycin
3
Injections
3
Everolimus
3
Albumin-Bound Paclitaxel
3
sapanisertib
2
olaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Transitional Cell
×
trilaciclib
×
Clear all
NCT04887831
2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2
Terminated
92 enrolled
24 charts